Non-Alcoholic Steatohepatitis (NASH) Treatment Market Report and Forecast 2023-2031

The global non-alcoholic steatohepatitis (NASH) treatment market size was valued at USD 6.2 billion in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period of 2023-2031 to reach a value of USD 10.3 billion by 2031. The market growth can be attributed to the increasing prevalence of NASH, obesity, and type 2 diabetes, along with the rising awareness about liver health.

Global Non-Alcoholic Steatohepatitis Treatment Market: Introduction

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation and damage to the liver, which can progress to cirrhosis and liver failure if left untreated. The primary risk factors for developing NASH include obesity, type 2 diabetes, and metabolic syndrome. The increasing prevalence of these conditions is driving the demand for NASH treatment. Other factors such as rising awareness about liver health, increasing government initiatives, and the growing demand for innovative treatment options are also expected to drive market growth.

Advancements in technology have played a significant role in the growth of the NASH treatment market. Digital health tools, such as telemedicine and online resources, have made NASH treatment more accessible to people who may have difficulty accessing traditional in-person care. This has expanded the reach of NASH treatment and helped to meet the growing demand for services.

Another factor contributing to the growth of the NASH treatment market is the changing attitudes towards liver health. In the past, liver diseases were often stigmatized and not discussed openly. However, in recent years, there has been a growing recognition of the importance of liver health, and a shift towards reducing the stigma associated with liver diseases. This has led to more people seeking treatment and an increased demand for NASH treatment services.

The NASH treatment market is expected to continue to grow in the coming years, as awareness of liver health concerns continues to increase, and new treatment options and technologies are developed to meet the needs of people with NASH. However, there are still significant barriers to accessing NASH treatment, particularly in low- and middle-income countries, where access to liver health services is often limited. Efforts are underway to address these barriers and improve access to NASH treatment globally.

Non-Alcoholic Steatohepatitis Epidemiology

According to the World Health Organization, approximately 25% of the global adult population is affected by NAFLD, with a significant proportion progressing to NASH. NASH can affect people of all ages and genders, but certain risk factors such as obesity, type 2 diabetes, and metabolic syndrome are more prevalent in specific age and gender groups.

It is essential to recognize that NASH and treatment needs can vary significantly among individuals within each age and gender category, and that NASH treatment should be tailored to meet the individual needs of each person. Efforts to improve access to NASH treatment should consider the unique needs of different age and gender groups, as well as the underlying factors that contribute to NASH, such as social determinants of health, genetics, and environmental factors. By addressing these factors, we can work towards reducing the burden of NASH and improving access to effective treatment for all individuals, regardless of age or gender.

Non-Alcoholic Steatohepatitis Treatment Market Segmentations

The market can be segmented based on drug type, by diagnosis, sales channel, treatment channel, and region:

Market Breakup by Drug Classification

Insulin Sensitizer

• Ocaliva Thiazolidinediones
• Biguanides
• Gucagon-like Peptide-1 Receptor Agonists
• Dipeptidyl Peptidase IV Inhibitors

Farnesoid X Receptor Agonists

• Ocaliva

Phenylimidazoles

• Selonsertib
• Vitamin E and Pioglitazone
• Elafibranor
• Cencicriviroc
• Others

Market Breakup by Diagnosis

• Blood Tests
• CT Scan
• MRI Scan
• Abdominal Ultrasound
• Liver Biopsy

Market Breakup by Sales Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Market Breakup by Treatment Channel

• Public
• Private

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Non-Alcoholic Steatohepatitis Treatment Market Analysis

The global non-alcoholic steatohepatitis treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of NASH, obesity, and type 2 diabetes, and the rising awareness about liver health. One key driver of growth in the NASH treatment market is the increasing prevalence of NASH and its risk factors.

North America is currently the largest market for NASH treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of NASH, a well-established healthcare infrastructure, and strong investment in liver health research and development. In addition, the growing adoption of digital liver health technologies, such as telemedicine and online resources, is further driving the growth of the market in North America. Europe is also a significant market for NASH treatment, the region's market growth is driven by factors such as a large population base, increasing awareness of liver health issues, and government initiatives to address liver health concerns.

Additionally, the region has a well-established healthcare system, which supports the delivery of NASH treatment. Asia Pacific is another region that is experiencing significant growth in the NASH treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of liver health concerns, and the growing adoption of digital liver health technologies. In addition, government initiatives to address liver health concerns are helping to drive the growth of the market in the region.

Key Players in the Global Non-Alcoholic Steatohepatitis Treatment Market

The report provides a detailed analysis of the key players involved in the NASH treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

• Genfit S.A
• Allergan Plc. (AbbVie Inc.)
• Zydus Lifesciences Ltd
• Conatus Pharmaceuticals, Inc
• Galmed Pharmaceuticals Ltd
• NeuroBo Pharmaceuticals Ltd
• Gilead Sciences, Inc
• Pfizer Inc
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Icon Plc
• Novo Nordisk A/S
• GlaxoSmithKline Plc